comparemela.com
  1. Home
  2. Live Updates
  3. Merck Vaxneuvance - Breaking News

Latest Breaking News On - Merck vaxneuvance - Page 1 : comparemela.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.

United statesTavo espinozaAmgen kyprolisTodd davisPaul haddenMatt hewittMatthew korenbergLawrence solowPrimrose bioMerck vaxneuvanceKaren reevesMattew korenbergMatt korenbergJazz pharmaceuticalsExchange commissionCraig hallum capital group

Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use

The FDA has expanded the approval of Vaxneuvance (pneumococcal 15-valent conjugate vaccine) to include 6 weeks through 17 years of age.

Eliav barrMerck vaxneuvanceMerck research laboratoriesDrug administrationBiologics license applicationMerck researchAccessed june

ACIP Recommends Updates to Pneumococcal Vaccination Guidelines

The Advisory Committee on Immunization Practices voted in favor of updates to the pneumococcal vaccination recommendations.

Merck vaxneuvanceCenters for diseasePfizer incHuman servicesUs department of healthDrug administrationAdvisory committee on immunization practicesDisease controlAdvisory committeeImmunization practicesMortality weekly

CDC panel levels playing field for new Merck, Pfizer pneumonia vaccines

BioPharma

Louise chenGeoffrey porgesMerck vaxneuvanceCenters for diseaseCantor fitzgeraldUs department of healthHuman servicesDrug administrationAdvisory committee on immunization practicesDive briefDisease controlAdvisory committeeImmunization practicesMortality weekly

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.